- Home
- DLB vs LEGN Comparison
DLB vs LEGN Comparison
Compare DLB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLB
- LEGN
- Stock Information
- Founded
- DLB 1965
- LEGN 2014
- Country
- DLB United States
- LEGN United States
- Employees
- DLB N/A
- LEGN N/A
- Industry
- DLB Multi-Sector Companies
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- DLB Miscellaneous
- LEGN Health Care
- Exchange
- DLB Nasdaq
- LEGN Nasdaq
- Market Cap
- DLB 7.9B
- LEGN 7.0B
- IPO Year
- DLB 2005
- LEGN 2020
- Fundamental
- Price
- DLB $78.22
- LEGN $30.71
- Analyst Decision
- DLB Strong Buy
- LEGN Strong Buy
- Analyst Count
- DLB 4
- LEGN 13
- Target Price
- DLB $98.25
- LEGN $79.42
- AVG Volume (30 Days)
- DLB 398.3K
- LEGN 1.5M
- Earning Date
- DLB 05-01-2025
- LEGN 05-13-2025
- Dividend Yield
- DLB 1.70%
- LEGN N/A
- EPS Growth
- DLB 36.08
- LEGN N/A
- EPS
- DLB 2.64
- LEGN N/A
- Revenue
- DLB $1,320,184,000.00
- LEGN $627,241,000.00
- Revenue This Year
- DLB $7.17
- LEGN $65.96
- Revenue Next Year
- DLB $4.69
- LEGN $52.55
- P/E Ratio
- DLB $28.53
- LEGN N/A
- Revenue Growth
- DLB 4.03
- LEGN 119.97
- 52 Week Low
- DLB $66.35
- LEGN $29.27
- 52 Week High
- DLB $89.66
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- DLB 56.13
- LEGN 39.14
- Support Level
- DLB $73.19
- LEGN $30.25
- Resistance Level
- DLB $77.75
- LEGN $33.30
- Average True Range (ATR)
- DLB 1.53
- LEGN 1.50
- MACD
- DLB 0.49
- LEGN -0.19
- Stochastic Oscillator
- DLB 92.69
- LEGN 25.12
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.